EXPERIMENTAL APPROACH
The plasma glucose-decreasing effects of AST and CAGwere monitored in KunMing mice by performing an OGTT test. Furthermore,
the effect of CAG on the metabolism of Zuker diabetic fat (ZDF)
rats was demonstrated after treatment for 5 weeks, as well as on
diabetes-relevant
clinical symptoms and glucose absorbance. The underlying molecular
mechanism of the therapeutic effects of CAG was explored in
both wild-type and sodium/glucose co-transporter 2 (SGLT2)-overexpressed
HEK293 cells.